Protagonist Therapeutics

ISIN US74366E1029

 | 

WKN A2AP32

Market cap (in EUR)
4,298 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States

Financials

Key metrics

Market capitalisation, EUR 4,298 m
EPS, EUR 0.57
P/B ratio 7.8
P/E ratio 126.6
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR 402 m
Net income, EUR 254 m
Profit margin 63.34%

What ETF is Protagonist Therapeutics in?

There are 4 ETFs which contain Protagonist Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Protagonist Therapeutics is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weight Investment focus Fund size (in m EUR)
Amundi MSCI Disruptive Technology UCITS ETF Acc 0.10%
Equity
World
Technology
Social/Environmental
Innovation
143
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.44%
Equity
United States
Health Care
Biotech
45
iShares S&P SmallCap 600 UCITS ETF 0.36%
Equity
United States
Small Cap
1,811
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0.08%
Equity
United States
Small Cap
185
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.